Physician profile
Paula Schleifer
NPI 1104952969
$30,759.27
in general payments reported to CMS, 2019-2025
36 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $165 · 2021: $585 · 2022: $1,522 · 2023: $14K · 2024: $1,725 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,587 · Honoraria: $1,650 · Travel and Lodging: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,590.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,720.00 |
| Food and Beverage | $2,586.83 |
| Honoraria | $1,650.00 |
| Travel and Lodging | $579.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $11,961.98 | 2023-2025 | Daybue |
| Genzyme Corporation | $6,540.00 | 2023 | |
| Immedica Pharma US, INC. | $5,781.44 | 2022-2025 | Ztalmy |
| Zevra Therapeutics INC | $1,650.00 | 2025 | Olpruva |
| Ucb, INC. | $1,489.55 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $515.42 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $467.17 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $269.21 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $261.74 | 2019-2022 | |
| Eisai INC. | $255.63 | 2019-2023 | |
| Biogen, INC. | $195.74 | 2020-2025 | Spinraza, Skyclarys |
| Zogenix INC. | $169.35 | 2021 | |
| Sumitomo Pharma America, INC. | $147.68 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $135.97 | 2021-2023 | Qelbree |
| Livanova USA, INC. | $123.92 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $118.76 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $112.56 | 2022-2023 | Jornay Pm |
| Catalyst Pharmaceuticals, INC. | $90.95 | 2023-2025 | Fycompa |
| Greenwich Biosciences, INC. | $81.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $77.08 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $70.89 | 2022-2025 | Zonisade, Eprontia |
| Corium, LLC | $49.27 | 2023-2025 | Azstarys |
| Abbvie INC. | $27.61 | 2023 | Botox |
| Aprecia Pharmaceuticals, LLC | $27.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.01 | 2019 | |
| Upsher-Smith Laboratories LLC | $23.45 | 2025 | |
| Aucta Pharmaceuticals, INC. | $21.57 | 2025 | Motpoly Xr |
| Merz Pharmaceuticals, LLC | $21.09 | 2023 | Xeomin |
| Neurocrine Biosciences, INC. | $18.55 | 2019 | |
| Chiesi USA, INC. | $15.66 | 2023 | Lamzede |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Schleifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.